Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208958 · ClinicalTrials.gov registry record · Phase 1
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Vedanta Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04208958 is a Phase 1 study that has completed, run by Vedanta Biosciences. The registered enrollment target is 56 participants.
The verdict
NCT04208958, a Phase 1 study, has completed, sponsored by Vedanta Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
Interventions
- DRUG Nivolumab
- DRUG Vancomycin Oral Capsule
- BIOLOGICAL VE800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04208958
The ClinicalTrials.gov registry entry for NCT04208958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vedanta Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04208958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04208958 about?
NCT04208958 is a clinical study titled "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer". This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
What is the current status of trial NCT04208958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2020-01-23. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04208958?
The interventions under investigation include: Nivolumab (DRUG), Vancomycin Oral Capsule (DRUG), VE800 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04208958?
This trial is sponsored by Vedanta Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.